Some insurers hesitate to embrace genetic testing

| | July 12, 2012
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

“For some people, the first symptom of this is cardiac arrest — they drop dead on the soccer field, the basketball court,” said Christman, sitting in his living room while his kids, all 12 years old and younger, played around him. “We have a chance to be a step ahead of the game here. You just think it’s a no-brainer for the insurance company.” But as genetic testing spreads, revolutionizing how doctors recognize and treat illness, the insurance industry is in a muddle. A genetic test one insurer calls “actionable,” another considers “unnecessary.” Some will pay to test sick patients, but not to find out who’s at risk.

View the original article here: Some insurers hesitate to embrace genetic testing – Chicago Tribune

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend